University Hospital in Motol-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2015

  1. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 859-870